Market Overview

RBC Looks For Post-Approval Data On MannKind

Related MNKD
Goldman Sachs Slams MannKind, Shares Down 9%
MannKind's Short Interest Has 'Grown High,' Analyst Says
MannKind: Use This Drop As An Opportunity (Seeking Alpha)

Shares of MannKind (NASDAQ: MNKD) have traded up as much as 11 percent Monday, following Friday's announcement by the company that AFREZZA has received FDA approval.

In response to the announcement, RBC Capital released a note stating that the next key catalysts the firm sees are post-approval data and a partnership, which the firm views as "likely."

Shares of Mannking are currently trading at $11.01, up 10.1 percent.

Posted-In: RBC CapitalAnalyst Color News FDA


Related Articles (MNKD)

Around the Web, We're Loving...

Get Benzinga's Newsletters